Loading clinical trials...

COMPLETED

Care EcoSystem: Ochsner Health System

The Dementia Care EcoSystem: The Feasibility of a Care Management Program Addressing Healthcare Quality, Access, and Cost for Patients With Dementia and Their Caregivers

NCT03916718•Ochsner Health System

View on ClinicalTrials.gov

Summary

1. To determine the feasibility and acceptability of the Care Ecosystem program in the Ochsner clinical setting. 2. To assess the effect of the Care Ecosystem program on health care cost and quality care quality as measured by primary outcome variables. * Adapted from the Care Ecosystem, memory.ucsf.edu/Care-Ecosystem

Eligibility

Age

55 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female ≥55 years of age at baseline
•Probable dementia diagnosis as evidenced by one or more of the following criteria:
•* Dementia listed on medical record problem list as of January 1, 2015 or later, or, in the opinion of the referring provider has dementia
•* Prescribed with any of the following: donepezil, memantine, galantamine HBR, rivastigmine, or tartrate; or, in the opinion of the referring provider, could take such medication
•Lives in community

Exclusion Criteria

•Documented history of Multiple Sclerosis, ALS, Traumatic Brain Injury, Huntington's Disease, Schizophrenia, Bipolar Disorder, or current Substance Abuse Disorder
•Lives in a nursing home or assisted living facility
•Unable to complete monthly telehealth or phone visits

Locations (1)

Ochsner Health System

New Orleans, Louisiana, United States

Key Dates

Start Date

February 26, 2019

Primary Completion Date

May 1, 2022

Completion Date

May 1, 2022

Last Updated

March 29, 2023

Enrollment

290

ACTUAL participants

Conditions

Dementia

Interventions

Care EcoSystem

BEHAVIORAL

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437

Autonomic FailurePure Autonomic Failure+3 more

View study

RECRUITINGPHASE3

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

NCT05508789

Alzheimer DiseaseDementia+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 29, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Care EcoSystem: Ochsner Health System

Inclusion Criteria

Exclusion Criteria

[18F]F-DOPA Imaging in Patients With Autonomic Failure

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Testing the Pain Clinical Practice Guideline

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

Circadian Rhythm and Other Factors in Memory Clinic Patients

Neurocognitive Assessment Platform 4 Alzheimer